Recent advances in immunotherapy for pancreatic cancer  

作　　者：Jeffrey Chi Rajvi Patel Hasan Rehman Shreya Goyal Muhammad Wasif Saif 

机构地区：[1]Department of Medical Oncology/Hematology,Donald&Barbara Zucker School of Medicine at Hofstra/Northwell,New York,NY 11042,USA

出　　处：《Journal of Cancer Metastasis and Treatment》2020年第1期531-547,共17页癌症转移与治疗（英文版）

摘　　要：Pancreatic ductal adenocarcinoma(PDAC)remains a disease with a dismal prognosis.Since 1996 there have only been two upfront regimens found to be superior to gemcitabine:FOLFIRINOX(5-fluorouracil,leucovorin,irinotecan and oxaliplatin),and gemcitabine plus nab-paclitaxel.Despite the improvement noted in these trials,PDAC is highly chemo-resistant and patients who respond will inevitably develop resistance.The unique immunosuppressive tumor microenvironment with extensive desmoplasia has posed challenges to developing new and effective treatments.Therapeutic vaccines,combination treatments,adoptive T cell transfer,as well as immunomodulators are being explored.With the emerging use of immunotherapy and immunomodulators,the scope of this review is to present the current data on these agents as well as focus on the advancements in the treatment of PDAC.Overall,results in this realm have been disappointing to date reflecting the non-immunogenic and complex tumor microenvironment of PDAC.

关 键 词：Pancreatic ductal adenocarcinoma CHEMORESISTANCE DESMOPLASIA tumor microenvironment extracellular matrix IMMUNOGENICITY IMMUNOTHERAPY vaccines immune checkpoint inhibitors IMMUNOMODULATION 

分 类 号：R73[医药卫生—肿瘤]